Page 4 - Per Protocol News Today

ENGLEWOOD, Colo., March 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the adva...

/PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Studying faster ventilator independence with minimally invasive diaphragm strengthening technology...

The injured officer was described by a department spokesperson as a nine-year department veteran and a military veteran.

Primary endpoint (PDFF) was achieved in both Intention to Treat and Per Protocol PopulationsVANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications,...

In the Phase IIb NATIVE, lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of NASHNATIVE

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

The Phase III TANGO study is the third trial to provide long-term evidence for Dovato, reinforcing its use as a viable switch option for people living with HIV For media and investors only ViiV

/PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and...